{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:14:49Z","timestamp":1788365689965,"version":"build-2803163510"},"reference-count":84,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024102","name":"SINTEF Industry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymthe.2026.06.034","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:40:23Z","timestamp":1782492023000},"page":"5284-5301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting vaccine fusion proteins to APCs increases immunogenicity of adenoviral and mRNA-LNP vaccines"],"prefix":"10.1016","volume":"34","author":[{"given":"Marlene Fyrstenberg","family":"Laursen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Combes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnar","family":"Gudjonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Bjerkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Parot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demo Yemane","family":"Tesfaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida J.","family":"Pettersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Molska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh Ram R.","family":"Visweswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve M.","family":"Labb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Draper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven Even","family":"Borgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarne","family":"Bogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0451-5936","authenticated-orcid":false,"given":"Ranveig","family":"Braathen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.06.034_bib1","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.3390\/pharmaceutics15071972","article-title":"Recent Advancement in mRNA Vaccine Development and Applications","volume":"15","author":"Al Fayez","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2026.06.034_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","article-title":"DNA vaccines: an historical perspective and view to the future","volume":"239","author":"Liu","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2026.06.034_bib3","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.3390\/cancers14235874","article-title":"DNA and mRNA Vaccines for Chronic Viral Infections and Cancer: Rationale, Mechanisms, and Progress","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2026.06.034_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2021.01.003","article-title":"Advances in gene-based vaccine platforms to address the COVID-19 pandemic","volume":"170","author":"Pushparajah","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2026.06.034_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250022","article-title":"Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity","volume":"53","author":"Provine","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110901","article-title":"Antigen bivalency of antigen-presenting cell-targeted vaccines increases B cell responses","volume":"39","author":"Hinke","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.06.034_bib7","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3389\/fimmu.2019.01086","article-title":"Endocytosis Deficient Murine Xcl1-Fusion Vaccine Enhances Protective Antibody Responses in Mice","volume":"10","author":"Gudjonsson","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/35078099","article-title":"B cells acquire antigen from target cells after synapse formation","volume":"411","author":"Batista","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.034_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/327059a0","article-title":"Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC","volume":"327","author":"Carayanniotis","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.034_bib10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.4049\/jimmunol.140.2.404","article-title":"Receptor-mediated B cell antigen processing. Increased antigenicity of a globular protein covalently coupled to antibodies specific for B cell surface structures","volume":"140","author":"Casten","year":"1988","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib11","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.4049\/jimmunol.162.6.3125","article-title":"Modulation of the humoral immune response by antibody-mediated antigen targeting to complement receptors and Fc receptors","volume":"162","author":"Baiu","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4049\/jimmunol.136.1.58","article-title":"Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin","volume":"136","author":"Kawamura","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib13","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2006-06-032938","article-title":"Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences","volume":"110","author":"Fredriksen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.06.034_bib14","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.ymthe.2005.10.019","article-title":"DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells","volume":"13","author":"Fredriksen","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.034_bib15","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/eji.200838302","article-title":"CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses","volume":"38","author":"Castro","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib16","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.4049\/jimmunol.139.5.1609","article-title":"Targeted antigen presentation using crosslinked antibody heteroaggregates","volume":"139","author":"Snider","year":"1987","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib17","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1128\/jvi.69.4.2357-2365.1995","article-title":"Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro","volume":"69","author":"Baier","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s002620050418","article-title":"Increased potency of Fc-receptor-targeted antigens","volume":"45","author":"Guyre","year":"1997","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2026.06.034_bib19","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/10883","article-title":"Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells","volume":"17","author":"Lunde","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1084\/jem.194.6.769","article-title":"Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo","volume":"194","author":"Hawiger","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.06.034_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1189\/jlb.1003481","article-title":"Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis","volume":"76","author":"Ruffini","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib22","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.molimm.2004.09.034","article-title":"Single chain antibody fragments for the selective targeting of antigens to dendritic cells","volume":"42","author":"Demangel","year":"2005","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib23","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.4049\/jimmunol.178.7.4169","article-title":"Delivery of Antigen to CD40 Induces Protective Immune Responses against Tumors","volume":"178","author":"Schjetne","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib24","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1172\/JCI34224","article-title":"The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells","volume":"118","author":"Nchinda","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.06.034_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2026.06.034_bib26","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/mt.2014.133","article-title":"A cationic nanoemulsion for the delivery of next-generation RNA vaccines","volume":"22","author":"Brito","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.034_bib27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/imm.12505","article-title":"CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes","volume":"146","author":"Lazzaro","year":"2015","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2026.06.034_bib28","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.034_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102083","article-title":"mRNA vaccine trafficking and resulting protein expression after intramuscular administration","volume":"35","author":"Hassett","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.06.034_bib30","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","article-title":"Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.034_bib31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41551-023-01082-6","article-title":"Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA","volume":"9","author":"Li","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2026.06.034_bib32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40824-023-00425-3","article-title":"mRNA nanodelivery systems: targeting strategies and administration routes","volume":"27","author":"Yuan","year":"2023","journal-title":"Biomater. Res."},{"key":"10.1016\/j.ymthe.2026.06.034_bib33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4049\/jimmunol.176.1.200","article-title":"The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity","volume":"176","author":"Yang","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/srep16756","article-title":"Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice","volume":"5","author":"Dicks","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.06.034_bib35","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.4049\/jimmunol.1000338","article-title":"CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling","volume":"185","author":"Lindsay","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib36","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2026.06.034_bib37","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.4049\/jimmunol.164.9.4635","article-title":"Increased DNA vaccine delivery and immunogenicity by electroporation in vivo","volume":"164","author":"Widera","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ymthe.2003.12.007","article-title":"Monoclonal antibodies produced by muscle after plasmid injection and electroporation","volume":"9","author":"Tjelle","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.034_bib39","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.vaccine.2006.11.042","article-title":"Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity","volume":"25","author":"Peng","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2026.06.034_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108069","article-title":"DNA vaccines: MHC II-targeted vaccine protein produced by transfected muscle fibres induces a local inflammatory cell infiltrate in mice","volume":"9","author":"L\u00f8v\u00e5s","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.06.034_bib41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/6995","article-title":"Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity","volume":"17","author":"Biragyn","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib42","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.4049\/jimmunol.1300504","article-title":"DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza","volume":"191","author":"Grodeland","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib43","doi-asserted-by":"crossref","first-page":"e01340-17","DOI":"10.1128\/JVI.01340-17","article-title":"A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza","volume":"91","author":"Andersen","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.720550","article-title":"APC-Targeted DNA Vaccination Against Reticulocyte-Binding Protein Homolog 5 Induces Plasmodium falciparum-Specific Neutralizing Antibodies and T Cell Responses","volume":"12","author":"Bjerkan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib45","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4049\/jimmunol.1901119","article-title":"Targeting Antigens to Different Receptors on Conventional Type 1 Dendritic Cells Impacts the Immune Response","volume":"205","author":"Fossum","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib46","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/eji.201445080","article-title":"Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus","volume":"45","author":"Fossum","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4049\/immunohorizons.1700038","article-title":"The Magnitude and IgG Subclass of Antibodies Elicited by Targeted DNA Vaccines Are Influenced by Specificity for APC Surface Molecules","volume":"2","author":"Braathen","year":"2018","journal-title":"Immunohorizons"},{"key":"10.1016\/j.ymthe.2026.06.034_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080008","article-title":"The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype","volume":"8","author":"Gr\u00f8deland","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.06.034_bib49","article-title":"Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules","volume":"4","author":"Andersen","year":"2019","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.ymthe.2026.06.034_bib50","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.4049\/jimmunol.1600893","article-title":"Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination","volume":"197","author":"Grodeland","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib51","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.vaccine.2018.12.049","article-title":"Needle-free delivery of DNA: Targeting of hemagglutinin to MHC class II molecules protects rhesus macaques against H1N1 influenza","volume":"37","author":"Mooij","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2026.06.034_bib52","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cell.2019.05.025","article-title":"Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies","volume":"178","author":"Alanine","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.06.034_bib53","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ncomms1615","article-title":"The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody","volume":"2","author":"Douglas","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.034_bib54","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nature10606","article-title":"Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum","volume":"480","author":"Crosnier","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.034_bib55","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature13715","article-title":"Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies","volume":"515","author":"Wright","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.034_bib56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41541-018-0071-7","article-title":"Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells","volume":"3","author":"Jin","year":"2018","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.ymthe.2026.06.034_bib57","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/eji.1830190711","article-title":"Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens","volume":"19","author":"Holte","year":"1989","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib58","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1053\/j.gastro.2011.04.048","article-title":"Tolerance to ingested deamidated gliadin in mice is maintained by splenic, type 1 regulatory T cells","volume":"141","author":"Du Pr\u00e9","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2026.06.034_bib59","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41467-024-44889-w","article-title":"Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins","volume":"15","author":"Hinke","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.034_bib60","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116147118","article-title":"A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants","volume":"118","author":"Pishesha","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.06.034_bib61","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/imm.13777","article-title":"Prevention and treatment of HPV-related cancer through a mRNA vaccine expressing APC-targeting antigen","volume":"172","author":"Li","year":"2024","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2026.06.034_bib62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41541-025-01089-x","article-title":"iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA","volume":"10","author":"Yanik","year":"2025","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.ymthe.2026.06.034_bib63","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.2147\/IJN.S463546","article-title":"An Immunoreceptor-Targeting Strategy with Minimalistic C3b Peptide Fusion Enhances SARS-CoV-2 RBD mRNA Vaccine Immunogenicity","volume":"19","author":"Chiu","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ymthe.2026.06.034_bib64","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ymthe.2026.06.034_bib65","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41467-025-68080-x","article-title":"Optimal murine CD4(+) T cell priming by mRNA-lipid nanoparticle vaccines requires endogenous antigen processing","volume":"17","author":"Rood","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.034_bib66","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41586-026-10353-6","article-title":"mRNA vaccines engage unconventional pathways in CD8+ T cell priming","volume":"654","author":"Jo","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.06.034_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-026-03099-z","article-title":"mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression","author":"Marks","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1294929","article-title":"Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design","volume":"14","author":"Clemente","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib69","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3390\/ph15070897","article-title":"The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery","volume":"15","author":"Kularatne","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ymthe.2026.06.034_bib70","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(24)00565-6","article-title":"Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4\/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4\/5 mRNA vaccine: a randomised phase 3 trial","volume":"25","author":"Okada","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.06.034_bib71","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.pt.2020.04.003","article-title":"The RH5-CyRPA-Ripr Complex as a Malaria Vaccine Target","volume":"36","author":"Ragotte","year":"2020","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib72","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1473-3099(24)00752-7","article-title":"Safety and efficacy of the blood-stage malaria vaccine RH5.1\/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children","volume":"25","author":"Natama","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2026.06.034_bib73","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ymthe.2023.03.012","article-title":"Neuraminidase delivered as an APC-targeted DNA vaccine induces protective antibodies against influenza","volume":"31","author":"Werninghaus","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.034_bib74","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2514356","article-title":"Developing the next-generation of adenoviral vector vaccines","volume":"21","author":"Sampson","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2026.06.034_bib75","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.06.034_bib76","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.ymthe.2026.06.034_bib77","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.cell.2019.03.048","article-title":"Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent Mechanism","volume":"177","author":"Watanabe","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.06.034_bib78","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-3083.2011.02639.x","article-title":"Generation of antibody-producing hybridomas following one single immunization with a targeted DNA vaccine","volume":"75","author":"\u00d8ynebr\u00e5ten","year":"2012","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib79","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-1759(97)00034-3","article-title":"Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells","volume":"204","author":"Norderhaug","year":"1997","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ymthe.2026.06.034_bib80","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1261\/rna.069286.118","article-title":"Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life","volume":"25","author":"Trepotec","year":"2019","journal-title":"Rna"},{"key":"10.1016\/j.ymthe.2026.06.034_bib81","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.06.034_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15476286.2024.2321764","article-title":"Urea supplementation improves mRNA in vitro transcription by decreasing both shorter and longer RNA byproducts","volume":"21","author":"Francis","year":"2024","journal-title":"RNA Biol."},{"key":"10.1016\/j.ymthe.2026.06.034_bib83","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.06.034_bib84","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12","volume":"27","author":"REED","year":"1938","journal-title":"Am. J. Epidemiol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626005113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626005113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:18:59Z","timestamp":1788362339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626005113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":84,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1525001626005113"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.06.034","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting vaccine fusion proteins to APCs increases immunogenicity of adenoviral and mRNA-LNP vaccines","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.06.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}